A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients
Revista: Bone Marrow Transplantation
Fecha: 01-mar-2004Oncología Radioterápica Oncología Médica Área de Terapia Celular Hematología y Hemoterapia
Extensive prior treatment with cytotoxic agents is associated with impaired mobilization of hematopoietic cells.
To assess the effect of a single course of standard-dose chemotherapy (CT), we compared the results of filgrastim-induced mobilization among two sequential groups of grade III-IV malignant glioma patients included in a hematopoietic transplantation program.
The first group (21 patients) had never been treated with CT until 2 days after surgery, when they received a course of 100 mg/m2 BCNU (i.v.) and 100 mg intracarotid cisplatin for cytoreduction (not for mobilization). At 1 month after this CT, they were mobilized with 12 microg/kg filgrastim. The second group (22 patients) was mobilized with the same dose of filgrastim directly after the surgery, without having ever received any prior CT.
The blood level of CD34+ cells was significantly lower in the CT-treated patients, both on the fourth day of filgrastim (15 vs 36 cells x 10(6)/l; P=0.01) and on the fifth (25 vs 58 cells x 10(6)/l; P=0.003), as it was the number of CD34+ cells collected per apheresis (1.3 vs 3.5 x 10(6)/l; P<0.0005).
The toxic effect of a single course of BCNU-cisplatin CT led to significant impairment of the filgrastim-induced mobilization response.
CITA DEL ARTÍCULO Bone Marrow Transplant. 2004 Mar;33(5):499-502
tal vezLE INTERESE
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.